Gamma scintigraphy and SPECT

Radiotracers in Drug Development

Volumn , Issue , 2006, Pages 269-289

  Newman, Stephen P ^a   Pitcairn, Gary R ^b  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b FUJIFILM Diosynth Biotechnologies   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 76649087247     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (71)

1. Maisey, M.N., Britton, K.E., and Gilday, B.L., Clinical Nuclear Medicine, 2nd ed., Chapman & Hall, London, 1991.
2. Parker, R.P., Smith, P.H.S., and Taylor, D.M., Basic Science of Nuclear Medicine, Churchill-Livingstone, New York, 1984.
3. Perkins, A.C., Nuclear Medicine: Science and Safety, John Libbey and Company, London, 1995.
4. Wagner, H.J., Hal Anger: nuclear medicine’s quiet genius, J. Nucl. Med., 44, 26, 2003.
5. Fleming, J.S., A history of the gamma camera: looking back to Anger, Scope, 6, 16, 1997.
6. Anger, H.O., Scintillation camera with multi-channel collimators, J. Nucl. Med., 5, 151, 1964.
7. Pitcairn, G.R. et al., Radionuclide imaging for assessing pulmonary drug delivery:SPECT imaging and a novel radiolabelling method, Drug Delivery Syst. Sci., 3, 5, 2003.
8. Davis, S.S. et al., Gamma scintigraphy in the evaluation of pharmaceutical dosage forms, Eur. J. Nucl. Med., 19, 971, 1992.
9. Meseguer, G., Gurny, R., and Buri, P., In vivo evaluation of dosage forms: application of gamma scintigraphy to non-enteral routes of administration, J. Drug Targeting, 2, 269, 1994.
10. Wilson, C.G., Application of gamma scintigraphy to modern dosage form design, Eur. J. Pharm. Sci., 2, 47, 1994.
11. Digenis, G.A. and Sandefer, E.P., Acceleration of pharmaceutical research and development with application of gamma scintigraphy, European Pharmaceutical Contractor, September, 22, 1999.
12. Wilding, I.R., Coupe, A.J., and Davis, S.S., The role of gamma scintigraphy in oral drug delivery, Adv. Drug Del. Rev., 46, 103, 2001.
13. Newman, S.P. et al., Radionuclide imaging technologies and their use in evaluating asthma drug deposition in the lungs, Adv. Drug Del. Rev., 55, 851, 2003.
14. Newman, S.P. and Illum, L., Radionuclide imaging studies in the assessment of nasal drug delivery in humans, Am. J. Drug Delivery, 2, 101, 2004.
15. Wilson, C.G., Assessing ocular drug delivery with lachrimal scintigraphy, Pharm. Sci. Technol. Today, 2, 321, 1999.
16. Washington, N. et al., A gamma scintigraphic study of gastric coating by Expidet, tablet and liquid formulations, Int. J. Pharm., 57, 17, 1989.
17. Brown, J., Haines, S., and Wilding, I.R., Colonic spread of three rectally administered mesalazine (Pentasa) dosage forms in healthy volunteers as assessed by gamma scintigraphy, Alimnet. Pharmacol. Ther., 11, 685, 1997.
18. Brown, J. et al., Spreading and retention of vaginal formulations in post-menopausal women as assessed by gamma scintigraphy, Pharm. Res., 14, 1073, 1997.
19. Davis, S.S. and Illum, L., Colloidal carriers and drug targeting, Acta Pharm. Technol., 32, 4, 1986.
20. Jones, T., New opportunities in molecular imaging using PET, Drug Inf. J., 31, 991, 1997.
21. Wilding, I.R., Scintigraphic evaluation of colonic delivery systems, STP Pharm. Sci., 5, 13, 1995.
22. Digenis, G.A. and Sandefer, E., Gamma scintigraphy and neutron activation techniques in the in vivo assessment of orally administered dosage forms, Crit. Rev. Ther. Drug Carrier Syst., 7, 309, 1991.
23. Pitcairn, G.R. et al., TechneCoat: a novel method for radiolabelling dry powder formulations in radionuclide imaging studies, in Respiratory Drug Delivery VIII, Dalby, R.N. et al., Eds., Davis Horwood, Raleigh, NC, 2002, p. 553.
24. Burch, W.M., Sullivan, P.J., and McLaren, C.J., Technegas: a new ventilation agent for lung scanning, Nucl. Med. Commun., 7, 865, 1986.
25. Conway, J.H. et al., Three-dimensional description of the deposition of inhaled terbutaline sulphate administered via Turbuhaler, in Respiratory Drug Delivery VII, Dalby, R.N. et al., Eds., Serentec Press, Raleigh, NC, 2000, p. 607.
26. Perkins, A. and Frier, M., Nuclear medicine imaging and drug delivery, Nucl. Med. Commun., 21, 415, 2000.
27. Dolovich, M., Hahmias, C., and Coates, G., Unleashing the PET: 3D imaging of the lung, in Respiratory Drug Delivery VII, Dalby, R.N. et al., Eds., Serentec Press, Raleigh, NC, 2000, p. 215.
28. Berridge, M.S., Lee, Z., and Heald, D.L., Regional distribution and kinetics of inhaled pharmaceuticals, Curr. Pharm. Des., 6, 1631, 2000.
29. Pozzi, F. et al., The TIME CLOCK system: a new oral dosage form for fast and complete release of drug after a predetermined time lag, J. Cont. Rel., 31, 99, 1994.
30. Dashe, C.K. et al., The distribution of nebulised isoproterenol and its effect on regional ventilation and perfusion, Am. Rev. Respir. Dis., 110, 293, 1974.
31. Walker, P.S. et al., An advanced and detailed in vitro validation procedure for the radiolabelling of carrier-free terbutaline sulphate dry powder, J. Aerosol Med., 14, 227, 2001.
32. Warren, S. et al., Gamma scintigraphic evaluation of a novel budesonide dry powder inhaler using a validated radiolabeling technique, J. Aerosol Med., 15, 15, 2002.
33. Hallworth, G.W., Particle size analysis of therapeutic aerosols, in Aerosols in Medicine:Principles, Diagnosis and Therapy, Morén, F. et al., Eds., Elsevier, Amsterdam, 1993, p. 351.
34. Snell, N.J.C. and Ganderton, D., Assessing lung deposition of inhaled medications, Respir. Med., 93, 123, 1999.
35. Wilding, I.R., Coupe, A.J., and Davis, S.S., The role of gamma scintigraphy in oral drug delivery, Adv. Drug Del. Rev., 7, 87, 1991.
36. Pitcairn, G.R. and Newman, S.P., Tissue attenuation corrections in gamma scintigraphy, J. Aerosol Med., 3, 187, 1997.
37. Lee, Z. et al., The effect of scatter and attenuation on aerosol deposition as determined by gamma scintigraphy, J. Aerosol Med., 14, 167, 2001.
38. Macey, D.J. and Marshall, R., Absolute quantitation of radiotracer uptake in the lungs using a gamma camera, J. Nucl. Med., 23, 731, 1982.
39. Pitcairn, G.R. et al., An improved method of quantifying aerosol deposition from scintigraphic images, in Proceedings of Drug Delivery to the Lungs XIII, The Aerosol Society, Portishead, Bristol, 2002, p. 31.
40. Everard, M.L. and Dolovich, M.B., In vivo measurement of lung dose, in Drug Delivery to the Lung, Bisgaard, H., O’Callaghan, C., and Smaldone, G.C., Eds., Marcel Dekker, New York, 2002, p. 173.
41. Warren, S. and Taylor, G., Quality control aspects of pharmaceutical gamma scintigraphy studies, European Pharmaceutical Contractor, March 2004.
42. Bondesson, E. et al., Planar gamma scintigraphy: points to consider when quantifying pulmonary dry powder aerosol deposition, Int. J. Pharm., 258, 227, 2003.
43. Perkins, A.C., Mann, C., and Wilson, C.G., Three-dimensional visualisation of the large bowel: a potential tool for assessing targeted drug delivery and colonic pathology, Eur. J. Nucl. Med., 22, 1035, 1995.
44. Berridge, M.S. et al., Biodistribution and kinetics of nasal C-11 triamcinolone acetonide, J. Nucl. Med., 39, 1972, 1998.
45. Dolovich, M.B., Measuring total and regional lung deposition using inhaled radiotracers, J. Aerosol Med., 14 (Suppl. 1), S35, 2001.
46. Fleming, J.S. and Conway, J.H., Three-dimensional imaging of aerosol deposition, J. Aerosol Med., 14, 147, 2001.
47. Pitcairn, G.R. et al., Lung penetration profiles: a new method for analyzing regional lung deposition data in scintigraphic studies, in Respiratory Drug Delivery VIII, Dalby, R.N. et al., Eds., Davis Horwood, Raleigh, NC, 2002, p. 549.
48. Pitcairn, G.R. et al., Radionuclide imaging for assessing pulmonary drug delivery:new methodologies for quantifying whole lung and regional lung deposition, Int. J. Pharm. Med., 17, 11, 2003.
49. Perring, S. et al., A new method of quantification of the pulmonary regional distribution of aerosols using combined CT and SPECT and its application to nedocromil sodium administered by metered dose inhaler, Br. J. Radiol., 67, 46, 1994.
50. Pitcairn, G.R. et al., Development of a standard method for quantifying regional lung deposition from SPECT and relating the data to airway anatomy, in Respiratory Drug Delivery IX, Dalby, R.N. et al., Eds., Davis Healthcare International, River Grove, IL, 2004, p. 621.
51. Fleming, J.S., Measuring drug deposition by airway generation in humans, in Respiratory Drug Delivery IX, Dalby, R.N. et al., Eds., Davis Healthcare International, River Grove, IL, 2004, p. 187.
52. Fleming, J.S. et al., Evaluation of the accuracy and precision of lung aerosol deposition measurements from single-photon emission computed tomography using simulation, J. Aerosol Med., 13, 187, 2000.
53. Fleming, J.S. et al., Comparison of methods for deriving aerosol deposition by aerosol generation from three-dimensional radionuclide imaging, J. Aerosol Sci., 31, 1251, 2000.
54. Pitcairn GR, Reader S, Pavia D. Deposition of corticosteroid aerosol in the human lung by Respimat soft mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J. Aerosol Med 2005; 18: 264-272.
55. Finlay, W.H. et al., Solving a major in vitro-in vivo correlation problem: impactor induction ports, in Respiratory Drug Delivery IX, Dalby, R.N. et al., Eds., Davis Healthcare International, River Grove, IL, 2004, p. 203.
56. Newman, S.P., Pitcairn, G.R., and Dalby, R.N., Drug delivery to the nasal cavity: in vitro and in vivo assessment, Crit. Rev. Ther. Drug Delivery Syst., 21, 21, 2004.
57. Suman, J.D. et al., Validity of in vitro tests on aqueous spray pumps as surrogates for nasal deposition, Pharm. Res., 19, 1, 2002.
58. Newman, S.P., Wilding, I.R., and Hirst, P.H., Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products?, Int. J. Pharm., 208, 49, 2000.
59. Ramsey, B.W. et al., Intermittent administration of inhaled tobramycin in patients with cystic fibrosis, N. Engl. J. Med., 340, 23, 1999.
60. Tarara, T.E., Weers, J., and Dellamary, L., Engineered powders for inhalation, in Respiratory Drug Delivery VII, Dalby, R.N. et al., Eds., Serentec Press, Raleigh, NC, 2000, p. 413.
61. Newhouse, M.T. et al., Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers, Chest, 124, 360, 2003.
62. Barnes, P.J., Pedersen, S., and Busse, W.W., Efficacy and safety of inhaled corticosteroids:new developments, Am. J. Respir. Crit. Care Med., 157, S1, 1998.
63. Partridge, M.R. et al., Chlorofluorocarbon-free inhalers: are we ready for the change?, Eur. Respir. J., 11, 1006, 1998.
64. Lipworth, B.J., Targets for inhaled treatment, Respir. Med., 94 (Suppl. D), S13, 2000.
65. Richards, J.C. et al., Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants, J. Aerosol Med., 14, 197, 2001.
66. Phipps, P.R. et al., Comparisons of planar and tomographic gamma scintigraphy to measure the penetration index of inhaled aerosols, Am. Rev. Respir. Dis., 139, 1516, 1989.
67. Newman, S.P. et al., Using gamma scintigraphy and single photon emission computed tomography to assess the pulmonary deposition of a new inhaled formulation of flunisolide, in Proceedings of Drug Delivery to the Lungs XIII, The Aerosol Society, Portishead, Bristol, 2002, p. 87.
68. Newman, S.P. et al., The distribution of an intranasal insulin formulation in healthy volunteers. Effect of different administration techniques, J. Pharm. Pharmacol., 46, 657, 1994.
69. Petri, W., Schmiedel, R., and Sandow, J., Development of a metered-dose nebulizer for intranasal peptide administration, in Transnasal Systemic Medications, Chien, Y.W., Ed., Elsevier Science Publishers, Amsterdam, 1985, p. 161.
70. Heyder, J. et al., Deposition of particles in the human respiratory tract in the size range 0.005 to 15 µm, J. Aerosol Sci., 17, 811, 1986.
71. Wilding, I.R. et al., In vivo evaluation of enteric-coated naproxen tablets using gamma scintigraphy, Pharm. Res., 9, 1436, 1992.